What makes NYR already a success is the fact that the mechanism of action of inhibiting calcium influx in the brain is already proven to reduce brain injury. What was the main issue was the length and side effects of that sustained inhibition. NYR-BO3 has solved both problems and dosed over many days plus avoiding neurotoxicity. But what makes it more exciting is that the same receptors on the brain are also found on the heart and it’s the only drug in the world to show significant protection of the heart upto 82 percent in pre clinical studies which are now cleared. Closest competition is Aptoll which has shown 40 percent protection but that deals with a totally different drug class and mechanism of action
AGN will succeed through to phase 3 and so will NYR. But the difference is NYR treats primary, secondary and cardiovascular injury. NYR on safety clearence coming up shortly will be on its way north of a 100 million market cap. Goes down comes straight back up and more. Bought more today and bought more AGN as well
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)